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A method of using the pulmonary trunk to form a
trileaflet valve
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Emmanuel Messas, MD,b,e Alain Carpentier, MD, PhD,d,f and David F. Torchiana, MD,a
Boston, Mass, and Paris, France
Replacement heart valves constructed from autologoustissues have been attempted, with significant varia-tions in long-term leaflet pliability and cellular via-bility.1-3 A new method of creating a potentially
viable trileaflet valve from autologous pulmonary artery was
investigated.
Materials and Methods
Human anatomic study. Using cadavers (n  7), the main
pulmonary trunk was removed and trimmed to create a tissue
cylinder with a height equal to the corresponding aortic annulus
diameter (Figure 1, A). Three longitudinal incisions, 2 mm less
than one half the cylinder height, were positioned 120° apart
(Figure 1, A). The resulting flaps were involuted and secured 2 to
3 mm from the superior rim of the cylinder with 6-0 polypropylene
(Prolene; Ethicon, Inc, Somerville, NJ) sutures passed through
adjacent flaps near their free edges and tied, making each a U stitch
(Figure 1, B-D). The base of the involuted tissue was joined with
additional 6-0 polypropylene sutures, creating interleaflet triangles
and eliminating acute corners from the inner surface of the valve
(Figure 1, E). The outermost wall was scalloped (Figure 1, D and
E).
Implantation was performed with a subcoronary, modified
freehand method (Figure 1, F and G). After removal of the
native leaflets, stay sutures were passed through the aortic
annulus at a position corresponding to the midpoint of each
excised leaflet. These were placed through the construct at the
superior cut edge (as opposed to the base of the valve in the
freehand method), and the construct was lowered into position
(Figure 1, F). A 6-0 polypropylene suture was run along the
superior aspect of the construct’s outermost wall, following the
commissural pillars’ contours (Figure 1, G). Passive testing of
each valve’s competency was
performed under a 200 mm Hg
saline column, enabling endo-
scopic inspection of the ne-
oleaflets. One aortic root was positioned in a flow simulator,
and transvalvular pressure gradients were determined across a
range of flows (1-6 L/min, 0.9% saline).
Sheep study. The valve design was tested in an adult sheep
model (n  2). Before each operation, a replacement valve
derived from the pulmonary trunk of a donor sheep was pas-
sively tested. The valve constructs were implanted as aortic
valve replacements in the subcoronary position by the modified
freehand technique described previously (Figure 1, F and G).
After weaning from cardiopulmonary bypass, the valves were
examined with an epicardial echocardiography probe. Regurgi-
tant flow was determined by continuous-wave Doppler scanning
in the long-axis view. Peak velocity was obtained in the one
animal in which anatomic alignment of the probe allowed
measurement. All animals received humane care in compliance
with the “Guide for the Care and Use of Laboratory Animals”4
prepared by the Institute of Laboratory Resources, National
Research Council.
Results
In 5 (71%) of the 7 cadavers, there was sufficient pulmonary artery
trunk tissue to construct competent aortic valve replacements by
the involution method (pulmonary trunk diameter, 23.7 3.3 mm;
pulmonary trunk length, 24.9  3.7 mm; aortic annulus diameter,
21.6  2.7 mm) (Figure 2). Under passive testing, these 5 valves
displayed symmetric 3-leaflet coaptation with no central orifice at
closure.
The human valve construct positioned in the flow simulator had
a transvalvular pressure gradient of 1 to 3 mm Hg across a range
of flows 1 to 6 L/min without evidence of acute angle bending of
the leaflet bases during leaflet opening. Both sheep implants dem-
onstrated mild aortic regurgitation with symmetric and pliable
leaflet mobility throughout the cardiac cycle. A peak pressure
gradient of 25 mm Hg was calculated by using the modified
Bernoulli equation (peak velocity of 2.49 m/s) in one animal with
a 14-mm aortic annulus diameter.
Discussion
Previous reports have described use of the autologous pulmonary
artery to create valve substitutes. The monocusp pulmonary valve
replacement has been used clinically in pediatric patients under-
going Ross procedures.5 In another method, a segment of the
pulmonary trunk was implanted in the subcoronary position and
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secured at 3 points to create a trileaflet aortic valve replacement.6
Concerns regarding surgical reproducibility and durability, partic-
ularly in the aortic position, have limited widespread clinical
application.
This study describes an efficient autologous tissue valve con-
struction method that offers several potential advantages: it might
be more reproducible because construction occurs before implan-
tation and more versatile because it can be transplanted to other
implant sites. As an aortic valve replacement, it might circumvent
the surgical risks and complications associated with a valve switch,
in part by preserving the native pulmonary valve. Alternatively, it
might offer a more suitable pulmonic valve replacement option
other than a homograft or moncusp during a Ross procedure.
Further investigations, including long-term animal studies, would
be useful to assess the clinical feasibility of this valve construct in
human patients.
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Figure 2. Photograph of valve construct derived from human
pulmonary artery by the involution method.
Figure 1. Involution method of valve construction and surgical implantation. A segment of the pulmonary artery
trunk was harvested and trimmed to a length (b) equal to the diameter of the corresponding aortic annulus. Three
longitudinal incisions, positioned 120° apart, were created such that the length (c) of each incision was slightly
less than one half the cylinder height (b; A). The resulting tissue flaps were involuted into the cylinder (B and C).
Sutures were passed through adjacent flaps and secured as U stitches near the superior rim of the tissue cylinder
(D). Additional U stitches secured the base of the involuted tissue to the outer cylinder, creating interleaflet
triangles (E). The construct wall between the commissures was scalloped (D and E). Implantation of the valve was
performed with a modified freehand technique, in which stay sutures are passed between the aortic annulus and
the superior cut edge of the valve construct (F). After the construct had been lowered into the subcoronary position,
a continuous 5-0 polypropylene suture was run along the superior aspect of the construct’s outermost wall (G).
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Stapled excision of the left atrial appendage
A. Marc Gillinov, MD, Gosta Pettersson, MD, PhD, and Delos M. Cosgrove III, MD, Cleveland, Ohio
The left atrial appendage (LAA) has been termed “ourmost lethal human attachment.”1 Excision or exclu-sion of the LAA is a component of most operations totreat atrial fibrillation (AF) and reduces late throm-
boemboli in patients with AF undergoing mitral valve surgery.2
However, surgical technique affects results, and incomplete
suture ligation increases risk of thromboembolism.2,3 We report
our experience with stapled excision and pericardial buttressing
of the LAA.
Methods
From January 2002 through December 2004, several suture and
stapling techniques were used to excise the LAA in more than 500
patients. Incomplete ligation and recanalization with suture tech-
niques and bleeding with unbuttressed staplers led us to the pro-
cedure described here.
Before manipulation of the heart, the LAA is examined by
intraoperative transesophageal echocardiography. If there is
thrombus, standard cut-and-sew technique is used to excise the
LAA. Otherwise, after cardioplegic arrest the Endo GIA II
stapler (United States Surgical Corporation, Norwalk, Conn)
with 4.8-mm staples is used to excise the LAA. Bovine peri-
cardial strips (Peri-Strips Dry; Synovis Surgical Innovations, St
Paul, Minn) buttress the staple line. The stapler is positioned
parallel to the base of the LAA and 3 to 5 mm from the
circumflex coronary artery, leaving a buttressed staple line on
the heart (Figure 1). The staple line and the region beneath the
staple line are examined for tears; any tears are repaired with
pledget-supported suture. Hospital charges are $317 for the
stapler and $246 for buttressing material.
Results
This buttressed stapling technique was used for LAA excision
in 222 patients. The most common indication for surgery was
mitral valve dysfunction (78%); in addition, 90% of patients
underwent a procedure for AF. Patients undergoing AF ablation
received 3 months of postoperative warfarin. All patients un-
derwent both intraoperative and predischarge echocardiograms.
There was no staple line bleeding; however, 10% of patients
required additional sutures beneath the staple line to repair tears.
There were 5 perioperative strokes (2%). In 1 of these patients,
there was laminar left atrial thrombus adjacent to a mitral biopros-
thesis. No other patient had left atrial thrombus seen on predis-
charge echocardiography. Reoperation for bleeding was required
in 7 cases (3%). In no case was the LAA the source of bleeding.
Discussion
In patients with AF, 90% of emboli responsible for strokes arise
from the LAA.1 It has been suggested that ligation of the LAA
reduces the risk of stroke in cardiac surgical patients with and
without preexisting AF.1,2,4 A variety of techniques have been
used for excision or exclusion of the LAA, but there are few
surgical devices designed specifically for this purpose.1,2,4,5
Suture ligation of the LAA is frequently incomplete, leaving
a communication that increases the risk of embolism.2,3 Non-
cutting staplers may be used to exclude the LAA; however,
staple lines frequently bleed, and we have observed late recan-
alization of the lumen. Cutting staplers ensure excision of the
trabeculated portion of the LAA, and pericardial buttressing
prevents staple line bleeding; however, fragile tissue beneath
the staple line may tear. Our current practice is to use a cutting
stapler with pericardial buttressing for excision of the LAA. As
instrumentation improves, we anticipate extension of LAA ex-
cision or exclusion to virtually all patients undergoing cardiac
surgery.
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